Correlation Between Enliven Therapeutics and UroGen Pharma

Can any of the company-specific risk be diversified away by investing in both Enliven Therapeutics and UroGen Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Enliven Therapeutics and UroGen Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Enliven Therapeutics and UroGen Pharma, you can compare the effects of market volatilities on Enliven Therapeutics and UroGen Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Enliven Therapeutics with a short position of UroGen Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Enliven Therapeutics and UroGen Pharma.

Diversification Opportunities for Enliven Therapeutics and UroGen Pharma

0.67

Correlation Coefficient

Enliven Therapeutics  UroGen Pharma

Poor diversification

The 3 months correlation between Enliven and UroGen is 0.67. Overlapping area represents the amount of risk that can be diversified away by holding Enliven Therapeutics and UroGen Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on UroGen Pharma and Enliven Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Enliven Therapeutics are associated (or correlated) with UroGen Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of UroGen Pharma has no effect on the direction of Enliven Therapeutics i.e., Enliven Therapeutics and UroGen Pharma go up and down completely randomly.

Pair Corralation between Enliven Therapeutics and UroGen Pharma

Given the investment horizon of 90 days Enliven Therapeutics is expected to generate 0.68 times more return on investment than UroGen Pharma. However, Enliven Therapeutics is 1.47 times less risky than UroGen Pharma. It trades about -0.09 of its potential returns per unit of risk. UroGen Pharma is currently generating about -0.14 per unit of risk. If you would invest  2,129  in Enliven Therapeutics on November 28, 2024 and sell it today you would lose (93.50) from holding Enliven Therapeutics or give up 4.39% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	95.45%
Values	Daily Returns

Enliven Therapeutics  vs.  UroGen Pharma

Enliven Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Enliven Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in March 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

UroGen Pharma

Risk-Adjusted Performance

Very Weak

Over the last 90 days UroGen Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in March 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Enliven Therapeutics and UroGen Pharma

The main advantage of trading using opposite Enliven Therapeutics and UroGen Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Enliven Therapeutics position performs unexpectedly, UroGen Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in UroGen Pharma will offset losses from the drop in UroGen Pharma's long position.

The idea behind Enliven Therapeutics and UroGen Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.